Trial · NCT07905014
Surface Electromyographic Analysis of Scapular Stabilizer Muscle in Postural Hyperkyphosis
NCT07905014, Not applicable, Not yet recruiting, Istinye University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Surface Electromyographic Analysis of Scapular Stabilizer Muscle in Postural Hyperkyphosis. Trials, record NCT07905014. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07905014
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Surface Electromyographic Analysis of Scapular Stabilizer Muscle in Postural Hyperkyphosis
- NCT number
- NCT07905014
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- Istinye University
- Conditions
- Hyperkyphosis
- Interventions
- Traditional Postural Exercises, Schroth-Based Corrective Exercises
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Scapular Stabilizer Muscle Activation | 4 weeks | Scapular stabilizer muscle activation will be assessed bilaterally using wireless surface electromyography (sEMG) during Schroth-based corrective and conventional postural exercises. Muscle activation of the serratus anterior, upper trapezius, middle trapezius, and lower trapezius will be recorded. EMG signals will be sampled at 1000-2000 Hz and band-pass filtered between 20-500 Hz. Root mean square (RMS) values obtained from the middle three seconds of the isometric holding phase will be normalized to each muscle's maximum voluntary isometric contraction (MVIC) and expressed as a percentage of MVIC (%MVIC). Mean normalized muscle activation values across three sets will be used to compare the two exercise approaches. |
| Secondary | Muscle Strength | 4 weeks | Bilateral isometric muscle strength of the serratus anterior, upper trapezius, middle trapezius, and lower trapezius will be assessed using a digital handheld dynamometer with the make-test technique. Each muscle will be evaluated through three maximal voluntary isometric contractions lasting five seconds each, with 30-second rest intervals between repetitions and one-minute rest intervals between muscles. The mean of the two highest measurements will be used for analysis. Higher values indicate greater isometric muscle strength. |
| Secondary | Thoracic Kyphosis Angle (Cobb Method) | 4 weeks | Thoracic kyphosis angle will be assessed using the Cobb method on standing lateral thoracic radiographs. The angle between the superior endplate of the T1 vertebra and the inferior endplate of the T12 vertebra will be measured in degrees (°). All radiographic measurements will be performed by the same radiologist. Greater angular values indicate increased thoracic kyphosis. |
| Secondary | Kyphosis Index | 4 weeks | Thoracic kyphosis will be assessed non-invasively using a flexible curve ruler (Flexicurve). With the participant standing upright, the ruler will be molded along the spinal curvature and transferred onto paper. The thoracic curvature length (L) and maximum kyphosis height (H) will be measured. The Kyphosis Index will be calculated using the formula: (H / L) × 100. Higher scores indicate greater thoracic curvature, and a score of 13 or higher will be considered indicative of hyperkyphosis. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07905014
GET https://conductscience.org/api/trials/v1/NCT07905014/registered